Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated ...
Model output · Signal date 2026-10-15
Helus Pharma Inc. (HELP) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Top 35%
of 4012 stocks scored
Rank correlation · 90D
18.0%
Spearman, 310 dates
Market Cap
$782M
small-cap · #60 of 60 peers
Summary
Helus Pharma Inc. (HELP) stock forecast summary
Our AI ranks Helus Pharma Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Helus Pharma Inc. is a small-cap company with a market capitalization of $782M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For HELP, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 310 forecast dates between 2023-06-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 352 forecast dates between 2023-06-29 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.4%, sell < -0.8%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, HELP included.
Follow HELP freePrice
HELP price chart and AI forecast
Cross-section · 2026-10-15
How HELP ranks among 4012 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2024-03-31
Helus Pharma Inc. (HELP) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in CAD and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | HELP | Rank |
|---|---|---|
| Market Cap | $782M | 60/60 |
Dividend & Shareholder Information
| Metric | HELP | Rank |
|---|---|---|
| Shares Outstanding | 75M | – |
Quarterly Financial Reports
HELP quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Helus Pharma Inc. (HELP) industry peers
Companies classified under the same SEC industry code as Helus Pharma Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| HELP Helus Pharma Inc. | ▲ | $782M |
| LLY Eli Lilly & Co | ▶ | $1.14T |
| JNJ Johnson & Johnson | ▼ | $611.90B |
| ONC Beone Medicines Ltd. | ▶ | $519.53B |
| ABBV Abbvie Inc. | ▶ | $500.94B |
| MRK Merck & Co., Inc. | ▶ | $363.59B |
| NVS Novartis Ag | ▼ | $280.27B |
| AZN Astrazeneca Plc | ▼ | $251.15B |
| ABT Abbott Laboratories | ▼ | $179.05B |
| NVO Novo Nordisk A S | ▼ | $169.41B |
| PFE Pfizer Inc | ▲ | $166.49B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $126.35B |
| BMY Bristol Myers Squibb Co | ▶ | $121.09B |
| GSK Gsk Plc | ▼ | $96.58B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $80.14B |
| SNY Sanofi | ▼ | $48.50B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B |
| RPRX Royalty Pharma Plc | ▲ | $33.92B |
| ZTS Zoetis Inc. | ▼ | $31.11B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $30.24B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $30.04B |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B |
| ZLAB Zai Lab Ltd | ▶ | $25.26B |
| ROIV Roivant Sciences Ltd. | ▶ | $24.28B |
| GMAB Genmab A/S | ▶ | $23.73B |
| UTHR United Therapeutics Corp | ▼ | $23.16B |
| INSM Insmed Inc | ▶ | $21.36B |
| VTRS Viatris Inc | ▶ | $20.03B |
| ASND Ascendis Pharma A/S | ▲ | $14.97B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.61B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.69B |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.07B |
| ELAN Elanco Animal Health Inc | ▼ | $11.27B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.63B |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.82B |
| CYTK Cytokinetics Inc | ▲ | $8.82B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.50B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.25B |
| ABVX Abivax S.A. | ▼ | $7.68B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.10B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.67B |
| ALKS Alkermes Plc. | ▲ | $6.56B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.16B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.04B |
| BLTE Belite Bio, Inc | ▲ | $6.01B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.88B |
| BLRX Biolinerx Ltd. | ▶ | $5.43B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B |
| ERAS Erasca, Inc. | ▲ | $5.14B |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B |
| PTCT Ptc Therapeutics, Inc. | ▶ | $4.98B |
| COGT Cogent Biosciences, Inc. | ▶ | $4.88B |
| MANE Veradermics, Inc | ▲ | $4.74B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $4.03B |
Where HELP sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Helus Pharma Inc. (HELP) stock news
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout
Helus Pharma buy thesis ahead of HLP003 Phase 3 APPROACH topline data (4Q26), cash runway/dilution risks, and 2028 NDA path.
Helus Pharma Sets Investor Presentation to Spotlight Late-Stage Mental Health Pipeline
Helus Pharma will host an investor presentation on October 21, 2026, featuring detailed updates on its lead drug candidates HLP003 and HLP004, as well as expert perspectives on the evolving treatment ...
FAQ
Helus Pharma Inc. (HELP) stock forecast FAQ
What is the Helus Pharma Inc. (HELP) stock forecast?
Our AI ranks Helus Pharma Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Helus Pharma Inc. stock predictions?
For HELP, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 310 forecast dates between 2023-06-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 5.0%, measured on 352 forecast dates between 2023-06-29 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Helus Pharma Inc. forecasts updated?
Helus Pharma Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Helus Pharma Inc.'s industry peers?
60 issuers in our coverage, HELP included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Beone Medicines Ltd. (ONC), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.